Blood Drugs News

News

Amarin: Amr101 Market Potential Far Greater Than High Triglycerides - Seeking Alpha
seekingalpha.com | Feb 10, 2012
< strong > By < a href='http://seekingalpha.com/author/Gary-Head' > Gary Head < /a > : < /strong > < p > I am the 1 person in every 500 people in most countries who has high cholesterol. I don't smoke, I exercise moderately, take Lipitor and attempt to take Niacin and Colestipol to reduce my

Statin Use Linked to Rare Autoimmune Muscle Disease, Study Finds - 12/07/2010
www.hopkinsmedicine.org | Jan 27, 2012
Johns Hopkins researchers have discovered how statins, the most commonly prescribed class of medication in the United States, appear to trigger a rare but serious autoimmune muscle disease in a small portion of the 30 million Americans who take the cholesterol-lowering drugs.

Pfizer Inc Lipitor Plan Might Not Be Worth It
www.biospace.com | Jan 25, 2012
Pfizer Inc. ’s strategy to keep its market share of cholesterol pill Lipitor may boost revenue without aiding profit, said the chief executive officer

Venous Thromboembolism (VTE) Therapeutics – Pipeline Assessment and Market Forecasts to 2018 | PRLog
www.prlog.org | Jan 9, 2012
Venous Thromboembolism (VTE) Therapeutics – Pipeline Assessment and Market Forecasts to 2018. The VTE Therapeutics Market is Forecast to Show Significant Growth Until 2018 - PR11766804

European Pharma Companies Set To Surge Ahead Of US Rivals - Pharmaceutical Technology
pharmtech.findpharma.com | Jan 5, 2012
The next two years may see a shake up in the world's current top pharmaceutical companies, with Pfizer likely to be the only US firm to remain in the top five by sales.

Pharma braces for patent cliff impact
www.rsc.org | Dec 22, 2011
Lipitor patent expires while familiar problems persist

Cholesterol-lowering medication accelerates depletion of plaque in arteries
www.eurekalert.org | Dec 14, 2011
In a new study, NYU Langone Medical Center researchers have discovered how cholesterol-lowering drugs called statins promote the breakdown of plaque in the arteries.

Pfizer tactics to combat generic drugmakers - FT.com
www.ft.com | Dec 5, 2011
Controversial tactics that Pfizer is using to protect revenues from sales of Lipitor, its top-selling cholesterol drug that lost patent protection last week, could become a model for the pharmaceutical industry as more companies lose exclusive

TGA warns against high dose simvastatin | 6minutes
www.6minutes.com.au | Nov 30, 2011
New dose limits and contraindications for simvasatin have been introduced by the TGA to reduce the risk of myopathy and rhabdomyolysis.

High doses of statins reduce plaque, reverse expected progression of coronary artery disease /
newsroom.heart.org | Nov 16, 2011
High doses of statins reduce plaque, reverse expected progression of coronary artery disease / American Heart Association AHA Newsroom, AHA News, heart news, heart health news, news releases, heart news releases, stroke news releases, stroke news, advocacy news, advocacy news releases, press